Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 61 results for asthma in children and management

  1. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .

    Medtech innovation briefing
    Published
    11 January 2017

  2. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

    Medtech innovation briefing
    Published
    11 January 2022

  3. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

    NICE guideline
    Published
    2 September 2025
    View recommendations

    Sections for NG250

  4. The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma

    Medtech innovation briefing
    Published
    11 August 2014

  5. Indoor air quality at home (NG149)

    This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.

    NICE guideline
    Published
    8 January 2020
    View recommendations

    Sections for NG149

  6. Increasing the dose of ICS within a personalised self-management programme for children and young people - For children and young people with asthma that is managed in primary care, is there an advantage to increasing the inhaled corticosteroid (ICS) dose when asthma control has deteriorated compared with using the usual dose in a self-management programme?

    ICS within a personalised self-management programme for children and young people - For children and young...

    Research recommendation
    Published
    6 August 2021

  7. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

    Medtech innovation briefing
    Published
    11 July 2016

  8. Otitis media with effusion in under 12s (NG233)

    This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.

    NICE guideline
    Published
    30 August 2023
    View recommendations

    Sections for NG233

  9. Diagnosing asthma in children and young people aged 5 to 16:- What is the acceptability and diagnostic accuracy of objective tests that could be used to comprisea diagnostic pathway for asthma in children and young people aged 5 to 16 (for example, exercise challenge, direct bronchial challenge with histamine or methacholine, indirect bronchial challenge with mannitol and peripheral blood eosinophil count)?

    Recommendation ID NG80/1 Question Diagnosing asthma in children and young people aged 5 to 16:- What is the acceptability...

    Research recommendation
    Published
    18 October 2018

  10. Improving adherence to asthma medication:- What are the most clinically and cost-effective strategies to improve medicines adherence in adults, young people and children with asthma who are non-adherent to prescribed medicines?

    Recommendation ID NG80/10 Question Improving adherence to asthma medication:- What are the most clinically and cost-effective strategies

    Research recommendation
    Published
    18 October 2018

  11. Second-line maintenance therapy in children and young people (under 16):- Is maintenance therapy more effective with a paediatric low dose of ICS plus a leukotriene receptor antagonist (LTRA) or with a paediatric low dose of ICS plus a long-acting beta2 agonist (LABA) in the treatment of asthma in children and young people (under 16) who have uncontrolled asthma on a paediatric low dose of ICS alone?

    Recommendation ID NG80/7 Question Second-line maintenance therapy in children and young people (under 16):- Is maintenance therapy more...

    Research recommendation
    Published
    18 October 2018

  12. Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and prognostic factors that indicate that a decrease in regular maintenance treatment is appropriate?

    Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the...

    Research recommendation
    Published
    18 October 2018

  13. Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or without LTRA:- What is the clinical and cost effectiveness of offering additional maintenance therapy to adults, young people and children with asthma that is uncontrolled on a moderate dose of ICS plus LABA with or without LTRA?

    Recommendation ID NG80/8 Question Additional maintenance therapy for asthma uncontrolled on a moderate dose of ICS plus LABA with or...

    Research recommendation
    Published
    18 October 2018

  14. Starting asthma treatment:- In adults, young people and children with asthma who have not been treated previously, is it more clinically and cost effective to start treatment with a reliever alone (a short-acting beta2 agonist [SABA]) or with a reliever (a SABA) and maintenance therapy (such as ICS)? Are there specificprognostic features that indicate that one of these treatment options may be more appropriate for some groups?

    ID NG80/6 Question Starting asthma treatment:- In adults, young people and children with asthma who have not...

    Research recommendation
    Published
    18 October 2018

  15. Monitoring asthma control using tele-healthcare:- What is the long-term (more than 12 months) clinical and cost effectiveness of using telehealthcare as a means to monitor asthma control in adults, young people and children? Methods of tele-healthcare can include telephone interview (with healthcare professional involvement) andinternet or smartphone-based monitoring support (no healthcare professional involvement).

    Recommendation ID NG80/5 Question Monitoring asthma control using tele-healthcare:- What is the long-term (more than 12 months) clinical

    Research recommendation
    Published
    18 October 2018